---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086860"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:55:15.646358+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin posts Q2 net loss $2.1M, reports positive clinical data for first Netherton Syndrome subject

## Summary
- Cash, equivalents and securities at June 30, 2023: ~$15.4M; runway extends into 2H 2024.
- Net loss Q2 2023: ~$2.1M vs ~$2.7M in Q2 2022; first-half 2023 loss ~$4.7M.
- First subject in open-label Netherton Syndrome study showed fully clear skin at QRX003 treatment sites and substantial pruritis improvement.
- Majority of patients across both Netherton Syndrome studies expected to be enrolled by end of August 2023.
- Regained Nasdaq minimum bid price compliance; closing bid price at $1.00+ for 10 consecutive days.

## SEC filing metadata
- accession: 0001104659-23-086860
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/0001104659-23-086860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/tm2322693d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086860
- JSON: https://secwatch.observer/filing/0001104659-23-086860.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086860.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t.
  - Period: quarter ended June 30, 2023
  - Net income: Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t
  - Result: reported results
  source text: On August 2, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/0001104659-23-086860-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.